Central Pharmaceuticals Valuation
Is CENTRALPHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of CENTRALPHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von CENTRALPHL für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von CENTRALPHL für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CENTRALPHL?
Other financial metrics that can be useful for relative valuation.
| What is CENTRALPHL's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ৳3.20b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 38.7x |
| Enterprise Value/EBITDA | -284.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CENTRALPHL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.6x | ||
ACTIVEFINE Active Fine Chemicals | 2.6x | n/a | ৳3.5b |
ADVENT Advent Pharma | 4.3x | n/a | ৳2.4b |
SILVAPHL Silva Pharmaceuticals | 3.3x | n/a | ৳2.1b |
SILCOPHL Silco Pharmaceuticals | 4.3x | n/a | ৳1.9b |
CENTRALPHL Central Pharmaceuticals | 35.6x | n/a | ৳3.2b |
Price-To-Sales gegen Gleichaltrige: CENTRALPHL ist auf der Grundlage des Price-To-Book Verhältnisses (3.9x) im Vergleich zum Durchschnitt der Vergleichsgruppe (1.3x) teuer.
Price to Earnings Ratio vs Industry
How does CENTRALPHL's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: CENTRALPHL ist teuer, wenn man sein Price-To-Book Verhältnis (4x) mit dem Asian Pharmaceuticals Branchendurchschnitt (2.2x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is CENTRALPHL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 35.6x |
| Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von CENTRALPHL für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.